Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of “Hold” from Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has been assigned a consensus recommendation of “Hold” from the thirteen research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $42.2222.

A number of analysts have weighed in on the stock. Royal Bank Of Canada upgraded shares of Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price objective for the company in a research note on Monday, August 10th. BTIG Research downgraded shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. Freedom Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, Citizens Jmp lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, August 10th.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 403,524 shares of company stock valued at $18,250,367. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of institutional investors have recently made changes to their positions in SION. Russell Investments Group Ltd. bought a new position in shares of Sionna Therapeutics during the 3rd quarter valued at $30,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth $31,000. State of Wyoming bought a new stake in shares of Sionna Therapeutics in the second quarter worth $35,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Sionna Therapeutics in the second quarter worth $44,000. Finally, Balyasny Asset Management L.P. purchased a new stake in Sionna Therapeutics during the fourth quarter valued at $58,000.

Sionna Therapeutics Trading Up 11.8%

Sionna Therapeutics stock opened at $6.25 on Wednesday. The business’s fifty day simple moving average is $35.11 and its two-hundred day simple moving average is $37.34. Sionna Therapeutics has a 12 month low of $4.01 and a 12 month high of $54.97. The company has a market capitalization of $282.56 million, a price-to-earnings ratio of -2.87 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, equities research analysts predict that Sionna Therapeutics will post -2.55 EPS for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.